Mer­ck touts PhI­II Keytru­da da­ta in front­line en­dome­tri­al can­cer

In a boost to Mer­ck’s ef­forts of mov­ing block­buster drug Keytru­da to ear­li­er lines of treat­ment, Phase III da­ta in en­dome­tri­al can­cer pa­tients show sig­nif­i­cant im­prove­ments in re­duc­ing the risk of dis­ease pro­gres­sion or death, the com­pa­ny re­vealed to­day.

Mer­ck high­light­ed how Keytru­da helped a broad swath of pa­tients, re­gard­less of their mis­match re­pair sta­tus — a mark­er of how well can­cer cells can re­pair er­ro­neous DNA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER